首页> 外文OA文献 >A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ Study

【2h】

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ Study

机译：一个现实世界，观测的，前瞻性研究，评估在一线治疗的前进过程中的表皮生长因子受体（EGFR）突变的分子流行病学与EGFR突变阳性局部先进或者的第一代或第二代EGFR酪氨酸激酶抑制剂转移性非小细胞肺癌：“悠久”的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Giannis Mountzios; Anna Koumarianou; Alexandros Bokas; Dimitrios Mavroudis; Epaminondas Samantas; Evangelos Georgios Fergadis; Helena Linardou; Panagiotis Katsaounis; Elias Athanasiadis; Michalis V. Karamouzis; George Pentheroudakis; Sofia Lampaki; Marios Froudarakis; Eleni-Isidora A. Perdikouri; Alvertos Somarakis; Foteini Papageorgiou; Zoe Paparepa; Aristeidis Nikolaou; Konstantinos N. Syrigos;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
3. MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+ [J] . F. Barata, H. Queiroga, E. Teixeira, Revista Portuguesa de Pneumologia (English Edition) . 2016,第5期

机译：MuTAR研究，II期，开放标签研究厄洛替尼（E）治疗在局部晚期或转移性非小细胞肺癌（mNSCLC）患者中出现酪氨酸激酶（TKI）域激活突变（MUT +）的患者（pts）表皮生长因子受体（EGFR）的研究，通过mNSCLC EGFR Mut +评价了1L在葡萄牙患者中的疗效
4. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
5. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, The oncologist . 2015,第3期

机译：吸烟状态对非小细胞肺癌患者无进展生存的作用
6. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
7. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
8. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界观测性前瞻性研究以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：悠久的研究
9. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界，观测性，前瞻性研究，以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：“悠久”的研究

著录项

引文网络

相似文献

相关主题

期刊订阅